Acumen Pharmaceuticals, Inc. ABOS
0.23 USD -0.01 (-2.95%)
At closeNov 11, 2026, 7:02 AM EST
0.23 0.00 +0.17%
Pre-market · Nov 11, 7:02 AM ET
0.229 Day range 0.2484
0.191 52-week range 3.60
- YTD
- -89.10%
- 1 year
- -87.83%
News
fool.com Acumen Pharmaceuticals: 3 Key Takeaways for Long-Term Investors Phase II ALTITUDE-AD trial top-line results are expected in November 2026. Cash reserves of $79 million will support operations into early 2027.
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) stock moved upwards by 16.2% to $4.67 during Monday's after-market session. The market value of their outstanding shares is at $9.1 million. Cerus…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) shares rose 211.2% to $1.88 during Monday's regular session. The company's market cap stands at $62.2 million. BeyondSpring (NASDAQ:BYSI) stock moved…
benzinga.com Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.
benzinga.com BTIG Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $1 BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $8 to $1.
benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session Gainers Inovio Pharmaceuticals (NASDAQ:INO) stock moved upwards by 292.6% to $2.37 during Friday's after-market session. The market value of their outstanding shares is at $79.8 million. Capricor…- benzinga.com Citigroup Downgrades Acumen Pharmaceuticals to Neutral, Lowers Price Target to $1 Citigroup analyst Geoff Meacham downgrades Acumen Pharmaceuticals (NASDAQ:ABOS) from Buy to Neutral and lowers the price target from $5 to $1.
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers CareDx (NASDAQ:CDNA) shares rose 22.2% to $87.42 during Friday's regular session. The company's market cap stands at $3.7 billion. As per the press release, Q3 earnings came out yesterday.…
benzinga.com Nasdaq Down Over 600 Points; Amazon Shares Fall Following Weak Q3 Results U.S. stocks fell Friday, with Nasdaq down 2.36% as Amazon missed Q3 estimates. Acumen plunged 85%, while oil rose 1.8% and gold fell 1.7%.- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 12.0% to $2.98 during Friday's pre-market session. The market value of their outstanding shares is at $115.1 million. Intensity…
benzinga.com Acumen Pharma Says ALTITUDE-AD Missed Primary, Key Secondary Endpoints In Alzheimer's Study; Co. To Cease Clinical Development Of Sabirnetug, Preserve Cash And Explore Strategic Options -- Topline data show that ALTITUDE-AD did not meet the primary endpoint of change from baseline in cognitive and functional decline as measured by the Integrated Alzheimer’s Disease Rating Scale…
benzinga.com Acumen Pharmaceuticals Q3 2026 Earnings Call Transcript Acumen Pharmaceuticals (NASDAQ:ABOS) reported third-quarter financial results on Monday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
benzinga.com Acumen Pharmaceuticals Q3 EPS $(0.35) Beats $(0.37) Estimate Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.37) by 5.41 percent. This is a 20.45 percent increase over losses…
benzinga.com Acumen Pharmaceuticals To Present New Phase 2 ALTITUDE-AD Data For Sabirnetug In Early Alzheimer’s Disease At CTAD 2026 Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of…
benzinga.com BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.
benzinga.com Acumen Announces New Findings Presented At AAIC 2026; JCR Collaboration Shows Improved Brain Penetration Of Anti‑Aβo Antibodies Via Transferrin Receptor Delivery In Mouse And Primate Models EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device…
benzinga.com Acumen Pharmaceuticals To Present Data On Three Trials At Alzheimer's Association International Conference 2026 Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of…- benzinga.com Acumen Pharmaceuticals Exercises Option For Development, Production, Commercialization Of Two Candidates To Treat Alzheimer's Disease Through JCR Pharmaceuticals' Blood-Brain Barrier -Penetrating Technology Platform J-Brain Cargo JCR Pharmaceuticals Co., Ltd. (TSE 4552; JCR), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced that Acumen…
- benzinga.com Acumen Pharmaceuticals Nominates Two Development Candidates In Its Enhanced Brain Delivery Program For Alzheimer's Disease Treatments, IND Submission Expected In Mid-2027 ACU301 and ACU401 were nominated in the EBD program as part of the exercise of Acumen's option under its license agreement with JCR PharmaceuticalsEBD technology represents the only anti-amyloid…
- benzinga.com Acumen Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript
benzinga.com Earnings Scheduled For May 12, 2026 - benzinga.com Acumen Pharmaceuticals Q1 EPS $(0.33) Beats $(0.36) Estimate Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 31.25 percent increase over losses…
- benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session
- benzinga.com Acumen Pharmaceuticals Files Prospectus To Resell Up To 10,833,331 Shares From March 16, 2026 Private Placement ACUMEN PHARMACEUTICALS, INC.Up to 10,833,331 shares of Common Stock This prospectus relates to the resale or other disposition from time to time by the selling stockholders identified in this
benzinga.com BTIG Reiterates Buy on Acumen Pharmaceuticals, Maintains $8 Price Target BTIG analyst Thomas Shrader reiterates Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and maintains $8 price target.- benzinga.com Acumen Pharmaceuticals Q4 EPS $(0.41) Beats $(0.43) Estimate Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.43) by 5.09 percent. This is a 33.87 percent increase over losses…
- benzinga.com Earnings Scheduled For March 26, 2026
- benzinga.com Acumen Pharma Announces New Research Findings At International Conference On Alzheimer's And Parkinson's Diseases And Related Neurological Disorders Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing novel therapeutics that target soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer's…
- benzinga.com Market-Moving News for March 16th NBIS: 17% | Nebius Announced 5-Year $12B AI Infrastructure Agreement With Meta To Provide Dedicated Capacity Across Multiple Locations Using NVIDIA Vera Rubin Platform Starting Early 2027 CTMX: 70%
benzinga.com Acumen Pharmaceuticals Announces Private Placement Of ~$35.75M At $3.30/Share Proceeds from the financing are expected to primarily support Acumen's Enhanced Brain Delivery (EBD) program, including ongoing preclinical development work to support the nomination of a lead…- benzinga.com Acumen Shares New Alzheimer's Drug Data At Global Brain Disease Conference Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of…
- benzinga.com 12 Health Care Stocks Moving In Friday's After-Market Session
benzinga.com Baker Hughes To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday - benzinga.com BTIG Maintains Buy on Acumen Pharmaceuticals, Raises Price Target to $7 BTIG analyst Thomas Shrader maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and raises the price target from $4 to $7.
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Pre-Market Session
- benzinga.com Acumen And JCR Pharma Collaborative Study Shows Improved Brain Distribution of AβO-Targeting Antibodies Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of…
- benzinga.com B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $8 B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $9 to $8.
- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com Preview: Acumen Pharmaceuticals's Earnings - benzinga.com 12 Health Care Stocks Moving In Thursday's Intraday Session Gainers PepGen (NASDAQ: PEPG) stock rose 114.3% to $5.7 during Thursday's regular session. The market value of their outstanding shares is at $87.2 million.
- benzinga.com B of A Securities Maintains Buy on Acumen Pharmaceuticals, Lowers Price Target to $9 B of A Securities analyst Geoff Meacham maintains Acumen Pharmaceuticals (NASDAQ:ABOS) with a Buy and lowers the price target from $10 to $9.
- benzinga.com Acumen Pharmaceuticals Q2 EPS $(0.68) Misses $(0.52) Estimate Acumen Pharmaceuticals (NASDAQ:ABOS) reported quarterly losses of $(0.68) per share which missed the analyst consensus estimate of $(0.52) by 31.53 percent. This is a 100 percent decrease over losses…
- benzinga.com Earnings Scheduled For August 12, 2025
- benzinga.com Acumen Pharmaceuticals's Earnings: A Preview
- benzinga.com Earnings Scheduled For May 13, 2025
- benzinga.com Earnings Scheduled For March 27, 2025
- benzinga.com Earnings Scheduled For November 12, 2024
- benzinga.com Earnings Scheduled For March 26, 2024 Companies Reporting Before The Bell • bluebird bio (NASDAQ:BLUE) is likely to report quarterly loss at $0.66 per share on revenue of $16.68 million.
benzinga.com Earnings Scheduled For November 13, 2023 Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.